Danaher Corporation $DHR Position Lifted by State of Alaska Department of Revenue

Key Points

• State of Alaska’s Department of Revenue increased its Danaher stake by 285.2% in the third quarter, bringing its holdings to 237,740 shares valued at approximately $52.7 million. Institutional investors collectively own 79.05% of Danaher.
• Danaher is expanding its AI strategy through a collaboration with NVIDIA and plans to launch its first AI-powered autonomous laboratory at commercial scale in early 2027, targeting faster drug discovery and laboratory research.
• Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and an average price target of $235.41. Danaher recently exceeded quarterly EPS and revenue expectations and declared a $0.40 quarterly dividend.

State of Alaska Department of Revenue increased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 285.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 237,740 shares of the conglomerate's stock after acquiring an additional 176,020 shares during the period. State of Alaska Department of Revenue's holdings in Danaher were worth $52,671,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Marquette Asset Management LLC grew its holdings in shares of Danaher by 192.1% during the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 73 shares during the last quarter. N.E.W. Advisory Services LLC bought a new position in Danaher during the 2nd quarter worth approximately $25,000. Main Street Group LTD purchased a new position in Danaher in the 1st quarter worth approximately $25,000. Field & Main Bank bought a new stake in Danaher in the second quarter valued at approximately $29,000. Finally, Evolution Wealth Management Inc. lifted its position in Danaher by 208.0% in the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 104 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a report on Saturday, October 10th. Evercore reissued an "outperform" rating and set a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. Royal Bank Of Canada raised their price target on shares of Danaher from $215.00 to $250.00 and gave the stock an "outperform" rating in a report on Monday, October 5th. Barclays boosted their price objective on shares of Danaher from $230.00 to $255.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. Finally, The Goldman Sachs Group boosted their price objective on shares of Danaher from $210.00 to $250.00 and gave the company a "buy" rating in a research report on Monday, September 21st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $235.41.

Danaher Stock Up 3.0%

NYSE:DHR opened at $231.52 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The firm's 50-day moving average price is $213.55 and its 200-day moving average price is $195.74. The company has a market capitalization of $162.76 billion, a PE ratio of 41.12, a P/E/G ratio of 2.82 and a beta of 0.76. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion during the quarter, compared to analysts' expectations of $6.12 billion. During the same period last year, the company posted $0.77 EPS. Danaher's revenue was up 5.5% on a year-over-year basis. On average, equities analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher's payout ratio is currently 28.42%.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.